The adventure of delta

Liver International

Volumn 36, Issue , 2016, Pages 135-140

  Rizzetto, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

HBsAg carriers; Hepatitis D; Hepatitis D Virus; Peg IFN therapy

Indexed keywords

ADEFOVIR; LONAFARNIB; PEGINTERFERON ALPHA; PREBIOTIC AGENT; RITONAVIR; TENOFOVIR; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS DELTA ANTIGEN; INTERFERON; VIRUS RNA;

ANTIVIRAL THERAPY; CLINICAL FEATURE; DELTA AGENT HEPATITIS; HEPATITIS DELTA VIRUS; HUMAN; NONHUMAN; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS LATENCY; VIRUS PATHOGENESIS; AFRICA; ASIA; BLOOD; EUROPE; GENETICS; HEPATITIS B VIRUS; HEPATITIS D; VIRUS REPLICATION;

AFRICA; ANTIVIRAL AGENTS; ASIA; EUROPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS D; HEPATITIS DELTA ANTIGENS; HEPATITIS DELTA VIRUS; HUMANS; INTERFERONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; VIRUS REPLICATION;

EID: 84952785935     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13018     Document Type: Review

References (44)

1. Smedile A, Rizzetto M. HDV: thirty years later. Dig Liver Dis 2011; 43(Suppl 1): S15-8.
2. Taylor JM. Virology of hepatitis D virus. Semin Liver Dis 2012; 32: 195-200.
3. Kuo MY, Sharmeen L, Dinter-Gottlieb G, Taylor J. Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol 1988; 62: 4439-44.
4. Been MD. HDV ribozymes. Curr Top Microbiol Immunol 2006; 307: 47-65.
5. Ferré-D'Amaré AR, Zhou K, Doudna JA. Crystal structure of a hepatitis delta virus ribozyme. Nature 1998; 395: 567-74.
6. Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades. In: Casey JL, eds. Hepatitis Delta Virus. Springer: Berlin, 2006; Vol. 307: 151-71.
7. He W, Ren B, Mao F, et al. Hepatitis D virus infection of Mice expressing human sodium taurocholate co-transporting polypeptide. PLoS Pathog 2015; 11: e1004840.
8. Tseng CH, Lai MM. Hepatitis Delta Virus RNA Replication. Viruses 2009; 1: 818-31.
9. Chang J, Nie X, Chang HE, Han Z, Taylor J. Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol 2008; 82: 1118-27.
10. Casey JL. RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol 2006; 307: 67-89.
11. Huang WH, Chen CW, Wu HL, Chen PJ. Post-translational modification of delta antigen of hepatitis D virus. Curr Top Microbiol Immunol 2006; 307: 91-112.
12. O'Malley B, Lazinski DW. Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen. J Virol 2005; 79: 1142-53.
13. Sureau C, Guerra B, Lanford RE. Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. J Virol 1993; 67: 366-72.
14. Jaoudé GA, Sureau C. Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J Virol 2005; 79: 10460-6.
15. Shih HH, Jeng KS, Syu WJ, et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J Virol 2008; 82: 2250-64.
16. Freitas N, Abe K, Cunha C, Menne S, Gudima SO. Support of the infectivity of hepatitis delta virus particles by the envelope proteins of different genotypes of hepatitis B virus. J Virol 2014; 88: 6255-67.
17. Flores R, Ruiz-Ruiz S, Serra P. Viroids and hepatitis delta virus. Semin Liver Dis 2012; 32: 201-10.
18. Flores R, Gago-Zachert S, Serra P, Sanjuán R, Elena SF. Viroids: survivors from the RNA world? Annu Rev Microbiol 2014; 68: 395-414.
19. Taylor J, Pelchat M. Origin of hepatitis delta virus. Future Microbiol 2010; 5: 393-402.
20. Negro F, Gerin JL, Purcell RH, Miller RH. Basis of hepatitis delta virus disease? Nature 1989; 341: 111.
21. Webb CH, Riccitelli NJ, Ruminski DJ, Lupták A. Widespread occurrence of self-cleaving ribozymes. Science 2009; 326: 953.
22. Dandri M, Lütgehetmann M. Mouse models of hepatitis B and delta virus infection. J Immunol Methods 2014; 2014: 39-49.
23. Ottobrelli A, Marzano A, Smedile A, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991; 101: 1649-55.
24. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-9.
25. Mederacke I, Filmann N, Yurdaydin C, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol 2012; 56: 115-22.
26. Giersch K, Helbig M, Volz T, et al. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. J Hepatol 2014; 60: 538-44.
27. Giersch K, Bhadra OD, Volz T, et al. Hepatitis delta virus can survive liver regeneration and is amplified through human cell division both in vitro and in vivo. J Hepatol 2015; 62: S187-3212.
28. Freitas N, Cunha C, Menne S, Gudima SO. Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles. J Virol 2014; 88: 5742-54.
29. Negro F, Hepatitis D virus coinfection and superinfection. In the hepatitis B and delta viruses. Cold Spring Harb Perspect Med 2014; 4: a021550.
30. Smedile A, Rizzetto M, Gerin JL. Advances in hepatitis D virus biology and disease. Prog Liver Dis 1994; 12: 157-75.
31. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis 2012; 32: 211-9.
32. Rizzetto M. Alavian hepatitis delta: the rediscovery. Clin Liver Dis 2013; 17: 475-87.
33. Rizzetto M. Hepatitis D virus: introduction and epidemiology. In: Seeger C, Locarnini S, eds. The Hepatitis B and Delta Viruses. Cold Spring Harbor perspectives in Medicine. Cold Spring Harbor Laboratory Press: New York, 2015; 305-13.
34. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005; 12: 2-9.
35. Triantos C, Kalafateli M, Nikolopoulou V, Burroughs A. Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther 2012; 35: 663-73.
36. Wedemeyer H, Yurdaydìn C, Dalekos GN, et al. ; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-31.
37. Wedemeyer H, Yurdaydin C, Ernst S, et al., Prolonged therapy of hepatitis delta for 96 weeks with Peg-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: the HIDIT-2 study. J Hepatol 2014; 60 (Abstr): S2-3.
38. Rizzetto M, Smedile A. Pegylated interferon therapy of chronic hepatitis D: in need of revision. Hepatology 2015; 61: 1109-11.
39. Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol 2014; 11: 68-71.
40. Heidrich B, Yurdaydin C, Kabaçam G, et al. ; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87-97.
41. Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015; 15: 1167-74. pii: S1473-3099(15)00074-2.
42. Yurdaydin C, Idilman R, Choong I, et al. Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis. J Hepatol 2015; 62;(Abstr): S235-61.
43. Volz T, Giersch K, Allweiss L, et al. Myrcludex-B inhibits establishment of HDV super-infection in HBV infected mice and reduces HDV viremia in stably HBV/HDV co-infected mice. J Hepatol 2015; 62 (Abstr): S514.
44. Bazinet M, Pantea V, Cebotarescu V, et al. Significant reduction of HBsAg and HDV-RNA by the nucleic acid polymer rep 2139 in Caucasian patients with chronic HBV/HDV co-infection. J Hepatol 2015; 62 (Abstr): S257-8.